Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01255423 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 206
- Enrollment target
NCT01255423 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 206 participants.
The verdict
NCT01255423, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 206 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of Diclofenac Sodium Topical (DSG) 1% compared with placebo applied four times a day in subjects with acute ankle sprains under 'in-use' conditions, in particular with regard to pain relief.
Interventions
- DRUG Placebo
- DRUG Diclofenac sodium topical gel 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01255423
The ClinicalTrials.gov registry entry for NCT01255423 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 206 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01255423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01255423 about?
NCT01255423 is a clinical study titled "Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain". The purpose of this study is to evaluate the efficacy of Diclofenac Sodium Topical (DSG) 1% compared with placebo applied four times a day in subjects with acute ankle sprains under 'in-use' conditions, in particular with regard to pain relief.
What is the current status of trial NCT01255423?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 206 participants. The study started on 2010-11. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01255423?
The interventions under investigation include: Placebo (DRUG), Diclofenac sodium topical gel 1% (DRUG).
Who is sponsoring clinical trial NCT01255423?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.